Sie sind hier: Startseite / Schwerpunkte / Zugang zu Medikamenten / Stimmen zum Entscheid des obersten Gerichtshofs / Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India

Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India

(Novartis, 1 April 2013) "A decision issued today by the Indian Supreme Court regarding the Novartis breakthrough medicine Glivec® (imatinib mesylate) provides clarification on Indian patent law and discourages innovative drug discovery essential to advancing medical science for patients."

www.novartis.com